๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for HR-positive, HER2-negative Advanced Breast Cancer

ABCSG 61 / TEODOR : Neoadjuvant TrEatment Optimization Driven by Circulating Tumor DNA and endOcrine Responsiveness NCT07084558NA14 sites๐Ÿ“ Vienna๐Ÿ“ Baden๐Ÿ“ Dornbirn Austrian Breast & Colorectal Cancer Study Group ยท Tests: blood sample for Signatera (TM) test, biopsy for Ki-67 assessment, FFPE tumor sample for Signatera (TM) test (archived) A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors NCT07318805Phase 113 sites๐Ÿ“ Duarte๐Ÿ“ Grand Rapids๐Ÿ“ Long Island City Pfizer ยท Tests: PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy NCT07071337Phase 32 sites๐Ÿ“ Beijing๐Ÿ“ Guangzhou Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ยท Tests: SKB264, Nab-paclitaxel, Paclitaxel, Capecitabine Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC. NCT06705127Phase 21 site๐Ÿ“ Hangzhou First Affiliated Hospital of Zhejiang University ยท Tests: TORIPALIMAB INJECTION(JS001 ), Stereotactic Body Radiation Therapy (SBRT) Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors NCT07288359Phase 1, Phase 216 sites๐Ÿ“ Atlanta๐Ÿ“ Nashville๐Ÿ“ San Antonio Novartis Pharmaceuticals ยท Tests: GVV858, Fulvestrant, Letrozole Dalpiciclib Plus Toremifene for First-line Advanced HR Positive and HER2 Negative Breast Cancer NCT06495515Phase 21 site๐Ÿ“ Tianjin Tianjin Medical University Cancer Institute and Hospital ยท Tests: Dalpiciclib๏ผŒToremifen Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study NCT06805812n/a24 sites๐Ÿ“ Aviano๐Ÿ“ Brescia๐Ÿ“ Catania Fondazione IRCCS Istituto Nazionale dei Tumori, Milano ยท Tests: Palbociclib, Ribociclib, Abemaciclib A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. NCT07062965Phase 3433 sites๐Ÿ“ Anchorage๐Ÿ“ Chandler๐Ÿ“ Gilbert Pfizer ยท Tests: PF-07248144, Fulvestrant, Everolimus, Exemestane A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors NCT07383506Phase 112 sites๐Ÿ“ Scottsdale๐Ÿ“ Los Angeles๐Ÿ“ Palo Alto Cogent Biosciences, Inc. ยท Tests: CGT6297 Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer. NCT07227233Phase 21 site๐Ÿ“ La Jolla University of California, San Diego ยท Tests: A CDK4/6 inhibitor different from the first that the participant had received, plus fulvestrant., Treatment of physiciaโ€ฆ Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors NCT05985655Phase 1, Phase 215 sites๐Ÿ“ Los Angeles๐Ÿ“ Grand Rapids๐Ÿ“ New York Exscientia AI Ltd., a wholly owned subsidiary of Recursion โ€ฆ ยท Tests: GTAEXS617, SoC A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer NCT05851014Phase 352 sites๐Ÿ“ Bengbu๐Ÿ“ Hefei๐Ÿ“ Hefei Genor Biopharma Co., Ltd. ยท Tests: GB491 combined with Letrozole, Placebo combined with Letrozole Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer NCT06982521Phase 3243 sites๐Ÿ“ Gilbert๐Ÿ“ Beverly Hills๐Ÿ“ Duarte Relay Therapeutics, Inc. ยท Tests: Zovegalisib, Capivasertib, Fulvestrant SNF Platform Study of HR+/ HER2-advanced Breast Cancer NCT05594095Phase 21 site๐Ÿ“ Shanghai Fudan University ยท Tests: PIK3CA inhibitor, AKT inhibitor, Carrelizumab, Famitinib, Fluzoparib A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors NCT07767474Phase 1, Phase 26 sites๐Ÿ“ Fort Worth๐Ÿ“ Houston๐Ÿ“ San Antonio Antares Therapeutics, Inc ยท Tests: ATX-898, ATX-898, ATX-898, ATX-898, ATX-898 FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer NCT05304962Phase 18 sites๐Ÿ“ La Jolla๐Ÿ“ Los Angeles๐Ÿ“ Port Saint Lucie Regor Pharmaceuticals Inc. ยท Tests: RGT-419B, RGT-419B in combination with hormonal therapy A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor NCT07612891Phase 1, Phase 21 site๐Ÿ“ Shanghai Shenzhen Ionova Life Sciences Co., Ltd. ยท Tests: INV-6452 Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer NCT06201234Phase 236 sites๐Ÿ“ Stuttgart๐Ÿ“ Tรผbingen๐Ÿ“ Winnenden GBG Forschungs GmbH ยท Tests: Olaparib + Elacestrant, Olaparib Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) NCT06757634Phase 3239 sites๐Ÿ“ Jonesboro๐Ÿ“ Little Rock๐Ÿ“ Duarte Celcuity Inc ยท Tests: Arm A: Gedatolisib + Palbociclib + Fulvestrant, Arm B: Ribociclib + Fulvestrant, Arm C: Gedatolisib + Palbociclib + Letโ€ฆ Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors NCT06726148Phase 1, Phase 233 sites๐Ÿ“ Los Angeles๐Ÿ“ Fort Myers๐Ÿ“ Boston Novartis Pharmaceuticals ยท Tests: ECI830, ribociclib, fulvestrant Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment NCT07281833Phase 316 sites๐Ÿ“ Anderlecht๐Ÿ“ Cologne๐Ÿ“ Essen Women's Cancer Study Group GmbH ยท Tests: Capivasertib Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors NCT06950086Phase 1, Phase 22 sites๐Ÿ“ Shanghai๐Ÿ“ Shanghai TYK Medicines, Inc ยท Tests: TYK-00540 Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) NCT05579366Phase 1, Phase 266 sites๐Ÿ“ Phoenix๐Ÿ“ Tucson๐Ÿ“ Los Angeles Genmab ยท Tests: Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer NCT07180160Phase 21 site๐Ÿ“ Shanghai Wenjin Yin ยท Tests: QL1706, CDK4/6 inhibitor, Fulvestrant First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors NCT05768139Phase 1, Phase 265 sites๐Ÿ“ Los Angeles๐Ÿ“ San Francisco๐Ÿ“ Aurora Eli Lilly and Company ยท Tests: STX-478, Fulvestrant, Ribociclib, Palbociclib, Letrozole A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy NCT05646862Phase 3210 sites๐Ÿ“ Greenbrae๐Ÿ“ Los Alamitos๐Ÿ“ Los Angeles Hoffmann-La Roche ยท Tests: Inavolisib, Fulvestrant, Alpelisib, Bupropion, Omeprazole Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM NCT06974604Phase 21 site๐Ÿ“ Providence Brown University ยท Tests: Dexamethasone oral Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer NCT04965766Phase 211 sites๐Ÿ“ Dijon๐Ÿ“ Limoges๐Ÿ“ Lyon Gustave Roussy, Cancer Campus, Grand Paris ยท Tests: U3-1402 Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer NCT06380751Phase 3306 sites๐Ÿ“ Gilbert๐Ÿ“ Fountain Valley๐Ÿ“ Glendale AstraZeneca ยท Tests: Saruparib (AZD5305), Camizestrant, Abemaciclib, Ribociclib, Palbociclib To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer NCT07368998Phase 234 sites๐Ÿ“ Los Angeles๐Ÿ“ Jacksonville๐Ÿ“ Kansas City Hoffmann-La Roche ยท Tests: Inavolisib, Fulvestrant
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy